Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC